CIK 0000899923 · Accelerated filer
MYRIAD GENETICS INC
Sign in to watch- Ticker
- MYGN
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 870494517
- Phone
- 801-584-3600
- Business address
- 322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
- Former names
- MYRIAD GENETICS INC
- 4 Grant or award Director acquired 59,701 shares (grant or award)
- 4 Grant or award Director acquired 59,701 shares (grant or award)
- 8-K Event Executive or director change · Shareholder vote results
- S-8 Other Securities Offered to Employees in Benefit Plans
- S-8 Other Securities Offered to Employees in Benefit Plans
- 4 Grant or award Chief Technology Officer acquired 251,889 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 7,500 shares at $3.69 ($27,638)
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Shares withheld for taxes Chief Commerical Officer gave up 55,975 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Operating Officer gave up 1,069 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Scientific Officer gave up 946 shares (to pay taxes)
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Shares withheld for taxes Chief Scientific Officer gave up 2,019 shares (to pay taxes)
Page 3 of 104 · 2,077 filings